Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Kymriah | tisagenlecleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | |||
| Kyprolis | Carfilzomib | Multiple Myeloma (relapsed) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kyprolis (with lenalidomide) | Carfilzomib (with lenalidomide) | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lancora | Ivabradine | Heart failure, NYHA class II or III | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | N/A | Complete | ||
| Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | ||
| Lartruvo | Olaratumab | Advanced Soft Tissue Sarcoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Latuda | lurasidone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Latuda | Lurasidone | Schizophrenia | List with criteria/condition | Complete | ||
| Latuda | Lurasidone | Schizophrenia | Do not list | Complete | ||
| Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
| Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | |||
| Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
| Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | ||
| Lenvima | Lenvatinib | Differentiated Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lenvima | Lenvatinib | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lenvima and Keytruda | lenvatinib and pembrolizumab | advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Leqembi | lecanemab | Alzheimer’s disease | Received | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Active | ||
| Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Complete |
Last Updated : June 30, 2024